We are revolutionizing the ability to dynamically observe disease and treatment response to produce better biomarkers, better trials, better drugs, and better outcomes. Our AI-enabled EV-Omics (EVO) platform enriches disease-associated extracellular vesicles (EVs)—through EVO, we offer reliable, blood-based discovery and detection of protein and RNA biomarkers.
Liquid biopsies for neurodegeneration, neuro-oncology, and antibody drug conjugate (ADC) applications
Leveraging the power of DNA, RNA, and protein data from extracellular vesicles for comprehensive multiomics insights of biology and disease
Clinical trial support, biomarker discovery, biomarker validation, translation of tissue markers to plasma
Our breakthrough EVO Platform employs SPARCs to enrich disease or tissue-associated EV subpopulations. Utilizing AI-enabled multiomic insights, EVO unravels the complexity of disease mechanism. This unparalleled view provided by our multiomics approach can transform drug development and precision medicine. Our team can be your partner at every stage of the drug development process and help your company upgrade its biomarker discovery and detection capabilities. We’re here to help at every step along the way.
Have we sparked your interest in partnering with us? We fuel new relationships, collaborations, and strategic partnerships. Let’s kindle the next generation of innovation together. To learn more about our services or to receive a quote, contact us.